Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager

Newron Pharmaceuticals SpA

SIX:NWRN

Watchlist

Dividends

Discount Rate

Price: 7.2 CHF -1.1% Market Closed

Market Cap: 140.1m CHF

Have any thoughts about
Newron Pharmaceuticals SpA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US		Fubotv Inc NYSE:FUBO	Media
US		Bank of America Corp NYSE:BAC	Banking
US		Palantir Technologies Inc NYSE:PLTR	Technology
US	C	C3.ai Inc NYSE:AI	Technology
US		Uber Technologies Inc NYSE:UBER	Road & Rail
CN		NIO Inc NYSE:NIO	Automobiles
US		Fluor Corp NYSE:FLR	Construction
US		Jacobs Engineering Group Inc NYSE:J	Professional Services
US		TopBuild Corp NYSE:BLD	Consumer products
US		Abbott Laboratories NYSE:ABT	Health Care
US		Chevron Corp NYSE:CVX	Energy
US		Occidental Petroleum Corp NYSE:OXY	Energy
US		Matrix Service Co NASDAQ:MTRX	Construction
US		Automatic Data Processing Inc NASDAQ:ADP	Technology
US		Qualcomm Inc NASDAQ:QCOM	Semiconductors
US		Ambarella Inc NASDAQ:AMBA	Semiconductors

Add Price Alert

Price Target:

Last Price: 7.2 CHF

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

NWRN Alert

Newron Pharmaceuticals SpA

7.2

-0.08 (-1.1%)

52 Week Range	4.23 10.96
Price Target

We'll email you a reminder when the closing price reaches CHF.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Fubotv Inc NYSE:FUBO	US
	Bank of America Corp NYSE:BAC	US
	Palantir Technologies Inc NYSE:PLTR	US
C	C3.ai Inc NYSE:AI	US
	Uber Technologies Inc NYSE:UBER	US
	NIO Inc NYSE:NIO	CN
	Fluor Corp NYSE:FLR	US
	Jacobs Engineering Group Inc NYSE:J	US
	TopBuild Corp NYSE:BLD	US
	Abbott Laboratories NYSE:ABT	US
	Chevron Corp NYSE:CVX	US
	Occidental Petroleum Corp NYSE:OXY	US
	Matrix Service Co NASDAQ:MTRX	US
	Automatic Data Processing Inc NASDAQ:ADP	US
	Qualcomm Inc NASDAQ:QCOM	US
	Ambarella Inc NASDAQ:AMBA	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Newron Pharmaceuticals SpA

What unique competitive advantages
does Newron Pharmaceuticals SpA hold over its rivals?

What risks and challenges
does Newron Pharmaceuticals SpA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Newron Pharmaceuticals SpA.

What unique competitive advantages
does Newron Pharmaceuticals SpA hold over its rivals?

What risks and challenges
does Newron Pharmaceuticals SpA face in the near future?

Has there been any significant insider trading activity
in Newron Pharmaceuticals SpA recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Newron Pharmaceuticals SpA.

Provide P/S
for Newron Pharmaceuticals SpA.

Provide P/E
for Newron Pharmaceuticals SpA.

Provide P/OCF
for Newron Pharmaceuticals SpA.

Provide P/FCFE
for Newron Pharmaceuticals SpA.

Provide P/B
for Newron Pharmaceuticals SpA.

Provide EV/S
for Newron Pharmaceuticals SpA.

Provide EV/GP
for Newron Pharmaceuticals SpA.

Provide EV/EBITDA
for Newron Pharmaceuticals SpA.

Provide EV/EBIT
for Newron Pharmaceuticals SpA.

Provide EV/OCF
for Newron Pharmaceuticals SpA.

Provide EV/FCFF
for Newron Pharmaceuticals SpA.

Provide EV/IC
for Newron Pharmaceuticals SpA.

Show me price targets
for Newron Pharmaceuticals SpA made by professional analysts.

What are the Revenue projections
for Newron Pharmaceuticals SpA?

How accurate were the past Revenue estimates
for Newron Pharmaceuticals SpA?

What are the Net Income projections
for Newron Pharmaceuticals SpA?

How accurate were the past Net Income estimates
for Newron Pharmaceuticals SpA?

What are the EPS projections
for Newron Pharmaceuticals SpA?

How accurate were the past EPS estimates
for Newron Pharmaceuticals SpA?

What are the EBIT projections
for Newron Pharmaceuticals SpA?

How accurate were the past EBIT estimates
for Newron Pharmaceuticals SpA?

Compare the revenue forecasts
for Newron Pharmaceuticals SpA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Newron Pharmaceuticals SpA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Newron Pharmaceuticals SpA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Newron Pharmaceuticals SpA compared to its peers.

Compare the P/E ratios
of Newron Pharmaceuticals SpA against its peers.

Discuss the investment returns and shareholder value creation
comparing Newron Pharmaceuticals SpA with its peers.

Analyze the financial leverage
of Newron Pharmaceuticals SpA compared to its main competitors.

Show all profitability ratios
for Newron Pharmaceuticals SpA.

Provide ROE
for Newron Pharmaceuticals SpA.

Provide ROA
for Newron Pharmaceuticals SpA.

Provide ROIC
for Newron Pharmaceuticals SpA.

Provide ROCE
for Newron Pharmaceuticals SpA.

Provide Gross Margin
for Newron Pharmaceuticals SpA.

Provide Operating Margin
for Newron Pharmaceuticals SpA.

Provide Net Margin
for Newron Pharmaceuticals SpA.

Provide FCF Margin
for Newron Pharmaceuticals SpA.

Show all solvency ratios
for Newron Pharmaceuticals SpA.

Provide D/E Ratio
for Newron Pharmaceuticals SpA.

Provide D/A Ratio
for Newron Pharmaceuticals SpA.

Provide Interest Coverage Ratio
for Newron Pharmaceuticals SpA.

Provide Altman Z-Score Ratio
for Newron Pharmaceuticals SpA.

Provide Quick Ratio
for Newron Pharmaceuticals SpA.

Provide Current Ratio
for Newron Pharmaceuticals SpA.

Provide Cash Ratio
for Newron Pharmaceuticals SpA.

What is the historical Revenue growth
over the last 5 years for Newron Pharmaceuticals SpA?

What is the historical Net Income growth
over the last 5 years for Newron Pharmaceuticals SpA?

What is the current Free Cash Flow
of Newron Pharmaceuticals SpA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Newron Pharmaceuticals SpA.

EV/EBIT
Enterprise Value to EBIT

-12.2

Current

-9.3

Median

16.6

Industry

Lower than median

Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT

-12.2

Enterprise Value

171.1m CHF

EBIT

-15m EUR

All Countries

Forward Multiples

			Market Cap	EV/EBIT
IT		Newron Pharmaceuticals SpA SIX:NWRN	137.1m CHF	-12.2
JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	776 550.9T JPY	-5 046 864.6
US		Eli Lilly and Co NYSE:LLY	710.5B USD	51
UK		Dechra Pharmaceuticals PLC LSE:DPH	440.4B GBP	17 702.3
DK		Novo Nordisk A/S CSE:NOVO B	3.3T DKK	27.8
US		Johnson & Johnson NYSE:JNJ	373.5B USD	16
US		Merck & Co Inc NYSE:MRK	251.1B USD	12.5
CH		Roche Holding AG SIX:ROG	202.7B CHF	11.8
CH		Novartis AG SIX:NOVN	183.3B CHF	14
UK		AstraZeneca PLC LSE:AZN	162.4B GBP	253.9
IE	E	Endo International PLC LSE:0Y5F	146B USD	587.7

				EBIT Growth
IT		Newron Pharmaceuticals SpA SIX:NWRN	Average EV/EBIT: 2 075.2 Negative Multiple: -12.2	N/A
JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	Negative Multiple: -5 046 864.6	N/A
US		Eli Lilly and Co NYSE:LLY	51	212%
UK		Dechra Pharmaceuticals PLC LSE:DPH	17 702.3	675%
DK		Novo Nordisk A/S CSE:NOVO B	27.8	85%
US		Johnson & Johnson NYSE:JNJ	16	29%
US		Merck & Co Inc NYSE:MRK	12.5	695%
CH		Roche Holding AG SIX:ROG	11.8	27%
CH		Novartis AG SIX:NOVN	14	54%
UK		AstraZeneca PLC LSE:AZN	253.9	131%
IE	E	Endo International PLC LSE:0Y5F	587.7	N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

EV/EBIT

33.8

2-Years Forward

EV/EBIT

97.4

3-Years Forward

EV/EBIT

52.6

Newron Pharmaceuticals SpA
SIX:NWRN

EV/EBIT
Enterprise Value to EBIT

EV/EBIT Forward Multiples

See Also

Company

Help

Tools

Stocks

Newron Pharmaceuticals SpA SIX:NWRN

EV/EBIT Enterprise Value to EBIT

EV/EBIT Forward Multiples

See Also

Company

Help

Tools

Stocks

Newron Pharmaceuticals SpA
SIX:NWRN

EV/EBIT
Enterprise Value to EBIT